Conditional Cash Transfers to Increase Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression: A Randomized Controlled Trial by Yotebieng, Marcel et al.
SUPPLEMENT ARTICLE
Conditional Cash Transfers to Increase Retention in PMTCT
Care, Antiretroviral Adherence, and Postpartum Virological
Suppression: A Randomized Controlled Trial
Marcel Yotebieng, MD, MPH, PhD,*† Harsha Thirumurthy, PhD, MPhil, MA,‡
Kathryn E. Moracco, PhD, MPH,§ Andrew Edmonds, PhD, MSPH,† Martine Tabala, Bs,k
Bienvenu Kawende, MD,k Landry K. Wenzi, MD,k Emile W. Okitolonda, MD, PhD,k
and Frieda Behets, PhD, MPH†¶
Background: Novel strategies are needed to increase retention in
prevention of mother-to-child HIV transmission (PMTCT) services. We
have recently shown that small, incremental cash transfers conditional
on attending clinic resulted in increased retention along the PMTCT
cascade. However, whether women who receive incentives to attend
clinic visits are as adherent to antiretrovirals (ARV) as those who do not
was unknown.
Objective: To determine whether HIV-infected women who received
incentives to remain in care were as adherent to antiretroviral treatment
and achieved the same level of viral suppression at 6 weeks postpartum
as those who did not receive incentives but also remained in care.
Methods: Newly diagnosed HIV-infected women at #32 weeks
gestational age were recruited at antenatal care clinics in Kinshasa,
Democratic Republic of Congo. Women were randomized in a 1:1
ratio to an intervention or control group. The intervention group
received compensation ($5, plus $1 increment at each subsequent
visit) conditional on attending scheduled clinic visits and accepting
offered PMTCT services, whereas the control group received usual
care. The proportion of participants who remained in care, were fully
adherent (took all their pills at each visit) or with undetectable viral
load at 6 weeks postpartum were compared across group.
Results: Among 433 women randomized (216 in intervention group
and 217 in control group), 332 (76.7%) remained in care at 6 weeks
postpartum, including 174 (80.6%) in the intervention group and 158
(72.8%) in the control group, (P = 0.04). Data on pill count were
available for 297 participants (89.5%), including 156 (89.7%) and 141
(89.2%) in the intervention and control groups, respectively; 69.9% (109/
156) and 68.1% (96/141) in the intervention and control groups had
perfect adherence [risk difference, 0.02; 95% CI: 20.06 to 0.09]. Viral
load results were available for 171 (98.3%) and 155 (98.7%) women in
the intervention and control groups, respectively; 66.1% (113/171) in the
intervention group and 69.7% (108/155) in the control group had an
undetectable viral load (risk difference, 20.04; 95% CI: 20.14 to 0.07).
Results were similar after adjusting for marital status, age, education,
baseline CD4 count, viral load, gestational age, and initial ARV regimen.
Conclusions: Although the provision of cash incentives to HIV-
infected pregnant women led to higher retention in care at 6 weeks
postpartum, among those retained in care, adherence to ARVs and
virologic suppression did not differ by study group.
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INTRODUCTION
The President’s Emergency Plan for AIDS Relief
(PEPFAR) goal of an AIDS-free generation, re-emphasized
in PEPFAR 3.0,1,2 will not be achieved without substantial
improvement in retention along the HIV care continuum
among women in maternal and child health (MCH) clinics in
resource-limited settings.
Over the past 2 decades, research has identified
increasingly effective interventions to prevent HIV trans-
mission and disease progression in infected individuals.
Successful antiretroviral therapy (ART) enables HIV-
infected people to live longer and remain healthier.3 Early
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initiation of ART delays the time to AIDS, serious non-AIDS
events, and mortality among HIV-infected adults.4–6 HIV-
infected adults on ART who have achieved virologic
suppression are 96% less likely to transmit the virus to sexual
partners.7 Moreover, results from the Promise Study showed
that the risk of mother-to-child transmission drops to 0.5%–
0.6% in pregnant women on ART.8 Thanks to the progress
spurred by the 2011 UNAIDS Global Plan for the Elimination
of New HIV Infection Among Children by 2015 and Keeping
their Mothers Alive, and an infusion of PEPFAR funding,
substantial progress has been achieved in increasing antire-
troviral (ARV) availability in low-resource settings, including
lifelong ART for pregnant women living with HIV.9–11 At the
end of 2013, 67% of HIV-infected pregnant women world-
wide were receiving ARVs for their own health or for the
prevention of mother-to-child HIV transmission (PMTCT).12
The WHO 2013 guidelines recommend lifelong ART for
all HIV-positive pregnant and breastfeeding women regardless
of CD4 count (Option B+),13 effectively transforming MCH
clinics into ART centers. However, in part because primary
health care systems are set up to primarily deliver episodic
acute care, high dropout rates along the HIV continuum of care
is a critical issue that is currently limiting the long-term impact
of PMTCT programs, particularly in sub-Saharan Africa where
90% of HIV-infected pregnant women live.
Data from early implementation of Option B+ in
Malawi showed that about 1 in 6 pregnant women initiated
on ART at antenatal care (ANC) registration did not return to
the clinic after their initial visit.14 A recent meta-analysis of
women lost to follow-up (LTFU) across the “PMTCT
cascade” found that 49% of HIV-infected pregnant women
are LTFU between ANC registration and delivery, and 34%
of mother-infant pairs are LTFU within 3 months of
delivery.15 Half of all vertical HIV transmissions are now
estimated to occur during the breastfeeding period when most
of the lactating women are not receiving ARV treatment.16 In
addition, less than 40% of HIV-exposed infants are tested for
HIV within the first 2 months of life in priority countries.12
Without substantial improvements to retention across the
PMTCT cascade, the PEPFAR goal of an AIDS-free
generation might not be achieved even if all HIV-infected
pregnant women were identified and initiated on ART.
Numerous interventions have been proposed to address
the retention challenge across the PMTCT cascade. A simple
search of clinicaltrials.gov for the term PMTCT shows
a number of ongoing or completed studies evaluating
strategies such as text messaging, peer support, community
health workers, conditional cash transfers, and more. We
recently completed a randomized controlled trial evaluating
the impact of conditional cash transfers on retention in and
uptake of PMTCT services in Kinshasa, Democratic Republic
of Congo (DRC). Previous results17 showed that providing
HIV-infected women with small and increasing cash trans-
fers, conditional on attending scheduled clinic visits and
accepting available PMTCT services, substantially increases
the proportion of women who remain in care and receive
available PMTCT services through 6 weeks postpartum.
However, as recently demonstrated in a large trial of pre-
exposure prophylaxis, adherence to scheduled visits and
participation in study procedures when there are incentives
conditioned on these specific behaviors do not always trans-
late to adherence to prophylactic treatment.18 Thus, whether
adherence to scheduled PMTCT visits and acceptance of
available services translates into better adherence to ART
remained to be tested.
This study assessed whether HIV-infected women who
received incentives to remain in care were as adherent to
ARV treatment and achieved the same level of viral
suppression at 6 weeks postpartum as those who did not
receive incentives but also remained in care.
METHODS
Study Design and Study Population
Between April 2013 and August 2014, 433 newly
diagnosed HIV-infected women, #32 weeks pregnant, regis-
tering for ANC at 89 clinics in Kinshasa, DRC were recruited
and randomized to receive either the standard of care or the
standard of care plus small and increasing cash payments.
These payments started at $5 and increased by $1 each
month, on the condition that the woman attended scheduled
clinic visits and, if requested, provided a blood sample for
a CD4 count, accepted referral for ART, delivered in a health
facility, and provided a blood sample for infant early HIV
diagnosis at 6 weeks postpartum. Analysis of the primary
endpoints of the trial (retention in and uptake of PMTCT
services) has been reported.17 Only participants who were
retained in care through the 6-week postpartum visit were
including in this analysis.
Outcomes
Two outcomes were considered for this analysis (1)
adherence to ARV drugs, and (2) viral load at 6 weeks
postpartum. Adherence was determined by pill counts. On the
basis of returned-product [zidovudine (AZT) or ART] counts
at each follow-up visit, clinics staff calculated mean adher-
ence as the number of pills not returned divided by the
number of days since the previous visit at which products
were dispensed. The calculated proportions were recorded in
the mother-infant register used by clinics to routinely monitor
PMTCT program implementation. At least once per month,
study staff visited the clinics and extracted the adherence
information from the register into an electronic database.
Participants with 100% adherence recorded at all visits were
classified as perfectly adherent; those with at least 1 visit with
adherence less than 100% were classified as nonadherent.
For viral load, at the time of enrollment, delivery, and
6-week postpartum visit, clinic staff obtained a blood sample
from each participant and prepared a dried blood spot [DBS
(5 spots of 50 mL of whole blood)] on Whatman paper, dried
at ambient temperature for a minimum of 3 hours, and then
placed in a Ziploc bag with desiccant packs. Drivers were sent
to pick up DBS samples and transport back to study
headquarters, where samples were stored at 220°C until they
were sent to the National AIDS Reference Laboratory in
Kinshasa (LNRS), where viral load was quantified using the
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m2000rt Real-Time HIV-1 assay (Abbott, Chicago, IL), with
a limit of detection of 40 copies per milliliter The LNRS
laboratory had experience with viral load quantification from
DBS and performed regular external quality control.19
Baseline Covariates
Baseline characteristics considered were participant age
in years, marital status (married/cohabitating or other), years
of education, gestational age at first ANC registration
dichotomized as early (,20 weeks) or not, initial PMTCT
regimen (AZT or ART), CD4 count (#350 or .350 cells/
mL), and viral load (undetectable or not) at enrollment. CD4
count was measured as part of routine PMTCT care using the
point-of-care Alere Pima Analyser (Alere Technologies, Jena,
Germany). DBS samples for viral load were collected as part
of the study (after the participant was enrolled, between 2 and
4 weeks after ANC registration).
Statistical Analysis
Proportions of participants in the intervention and control
groups who were fully adherent or with an undetectable viral
load at 6 weeks postpartum were compared using Pearson’s x2
tests. Linear risk models were used to estimate unadjusted risk
differences (RD) and 95% CI. Generalized estimating equations
were used to adjust for potential clustering at the clinic level.
Analyses were also adjusted for any baseline characteristic that
was found to be imbalanced between groups or hypothesized as
a strong predictor of either outcome. All analyses were
completed using SAS 9.3 (SAS Institute Inc., Cary, NC). All
tests were 2-sided and used a 0.05 significance level.
The study is approved by the Institutional Review
Board of the Ohio State University and the Ethical Committee
of the Kinshasa School of Public Health. This trial is
registered at ClinicalTrials.gov, number NCT01838005.
RESULTS
At 6 weeks postpartum, 332 (76.7%) total participants
were retained in care, 80.6% (174/216) of the intervention
group and 72.8% (158/217) of the control group (P = 0.04). At
baseline, participants had a median age of 29 years (inter-
quartile range 25–34) and a median of 10 years of education
(interquartile range 8–12). Most participants (83.4%) were
married or cohabitating, 19.9% initiated ANC before 20 weeks
of gestation, and 23.2% were initiated on ART as the initial
PMTCT regimen. Over half (51.8%) of participants had an
undetectable viral load, and 44.7% had a CD4 count less than
or equal to 350 cells per milliliter. Baseline characteristics did
not differ by study group (Table 1).
Overall, pill count data from all clinic visits were
available for 297 participants (89.5%), including 156 (89.7%)
and 141 (89.2%) of the intervention and control groups,
respectively. Among these participants, 69.9% (109/156) in
the intervention group and 68.1% (96/141) in the control
group were classified as adherent (RD 0.02; 95% CI: 20.06
to 0.09) (Table 2). Initiation of ANC before 20 weeks of
gestation was the only baseline characteristic that was
statistically associated with adherence (RD 20.18; 95% CI:
20.31 to 20.06). Adjusting for baseline characteristics did
not change the association between intervention group and
adherence (adjusted RD 0.03; 95% CI: 20.05 to 0.12).
At 6 weeks postpartum, viral load measurements were
available for 171 (98.3%) and 155 (98.7%) participants in the
intervention and control groups, respectively. Among these
participants, 66.1% (113/171) in the intervention group and
69.7% (108/155) in the control group had an undetectable
viral load (RD 20.04; 95% CI: 20.14 to 0.07) (Table 3).
Undetectable viral load at baseline was a statistically signif-
icant predictor of undetectable viral load at 6 weeks post-
partum; 84.3% (140/166) of participants with an undetectable
viral load at study enrollment had an undetectable viral load at
6 weeks postpartum compared with 50.3% (78/155) of
participants with a detectable viral load at baseline (RD
0.34; 95% CI: 0.26 to 0.42). Similarly, participants whose
initial PMTCT regimen was ART were more likely to achieve
an undetectable viral load at 6 weeks postpartum compared
with those who initially received AZT (RD 0.14; 95% CI:
0.01 to 0.26). In multivariable analysis adjusting for all
baseline covariates, the adjusted RD comparing the propor-
tions of participants in the study groups with an undetectable
viral load at 6 weeks postpartum was 20.01 (95% CI: 20.10
to 0.08).
DNA polymerase chain reaction test results were
available for 325 infants; 169 and 156 in the intervention
and control groups, respectively. Of those infants, 5 (3.0%) in
the intervention group and 6 (3.9%) in the control group
tested positive.
TABLE 1. Characteristics of the 332 Participants Retained in
PMTCT Care Through 6 Weeks Postpartum by Study Group
Study Group
PIntervention Control
Age in years: median (IQR) 29.0 (25.0–34.0) 28.0 (25.0–34.0) 0.4931
Maternal education in years:
median (IQR)
10.0 (8.0–12.0) 10.0 (8.0–12.0) 0.6528
Marital status
Married/cohabiting 146 (84.4) 130 (82.3) 0.6057
Divorced/separated/
widow/never married
27 (15.6) 28 (17.7)
CD4 count
#350 73 (46.2) 58 (57.0) 0.5789
.350 85 (53.8) 77 (43.0)
Gestational age in weeks:
median (IQR)
,20 wk 36 (20.7) 30 (19.0) 0.6979
$20 wk 138 (79.3) 128 (81.0)
Baseline viral load
Undetectable 89 (52.0) 80 (51.6) 0.9376
Detectable 82 (48.0) 75 (48.4)
Initial PMTCT regimen
AZT 37 (21.6) 38 (24.8) 0.4955
ART 134 (78.4) 115 (75.2)
IQR, interquartile range.
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DISCUSSION
Data from a pre-exposure prophylaxis trial have shown
that, when incentivized, participants may attend study visits
and undergo study procedures yet not take their prophylactic
drugs.18 This analysis found that among participants who
were successfully retained in care through 6 weeks post-
partum, nearly 70% were perfectly adherent to ART but that
adherence did not differ between study groups suggesting that
providing cash incentives did not influence adherence among
those retained in care. Similarly, over two-thirds of women
retained in care achieved viral suppression at 6 weeks
postpartum, but this did not differ between study groups
either, providing further evidence that those who were
retained in care as a result of receiving the cash incentive
were as adherent to those who would have been retained in
care without the incentive.
Incomplete adherence to ART has been found to be
associated with a lack of financial support.20 Subgroup
analysis of the primary aims of the trial reported elsewhere17
found that women in the lower wealth quintiles were more
likely to be retained in care if they received the cash
incentives. Our findings that there is no difference in
adherence by study group suggest that the association
between financial support and adherence is mostly mediated
through retention. Conditional cash transfers made directly to
vulnerable women might increase their control over financial
resources and allow them to overcome barriers to clinic
attendance such as transportation costs and opportunity costs
of time. Adherence to ARVs was not a conditionality for
receiving the cash incentives in this study and the cash
incentives intervention did not affect adherent behavior
among participants retained in care. Given this, more in-
depth examinations, including qualitative analyses of the
mechanisms by which cash incentive interventions increase
desired PMTCT outcomes (retention in care and uptake of
services), are needed to (1) enhance our understanding of how
these interventions work and (2) improve our ability to design
and scale-up similar interventions for PMTCT and other
health and social issues.
Over 30% of participants were not adherent to their
ARVs, data consistent with what has been observed in HIV-
infected women elsewhere.20 About 69% of women had an
undetectable viral load at 6 weeks, a proportion that is similar
to the 71% reported in a prospective cohort of pregnant
women in Benin.21 Receiving ART as the initial PMTCT
regimen, having an undetectable viral load at baseline, and
having started ANC before 20 weeks of gestation were all
correlated with viral suppression at 6 weeks postpartum. In
late 2014, DRC began rolling out the WHO’s Option B+,
which will help increase the proportion of pregnant women
with an undetectable viral load and lower the risk of mother-
to-child transmission. This is a step toward enhanced
PMTCT, however, to further optimize PMTCT outcomes,
additional efforts are needed to encourage pregnant women to
start ANC visits as early as possible. Although 88% of
pregnant women in DRC attend at least 1 ANC visit before
TABLE 2. Crude and Adjusted Differences in the Proportions of Participants Who Adhered to Antiretrovirals for the Prevention of
Mother-to-Child Prevention at 6 Weeks Postpartum, by Study Group
Adherence to ARVs
Yes (N = 205)* No (N = 92)* RD (95% CI) Adjusted RD (95% CI)†
Group
Intervention 109 (69.9) 47 (30.1) 0.02 (20.06 to 0.09) 0.03 (20.05 to 0.12)
Control 96 (68.1) 45 (31.9)
Age in years: median (IQR) 28.0 (25.0 to 34.0) 29.5 (25.5 to 34.0) 20.01 (20.01 to 0.00) 20.01 (20.02 to 0.00)
Maternal education in years: median (IQR) 10.0 (8.0 to 12.0) 10.0 (8.0 to 12.0) 0.00 (20.01 to 0.02) 0.01 (20.01 to 0.02)
Marital status
Divorced/separated/widow/never married 29 (63.0) 17 (37.0) 20.07 (20.23 to 0.09) 20.13 (20.30 to 0.05)
Married/cohabiting 175 (70.0) 75 (30.0)
CD4 count
#350 80 (70.8) 33 (29.2) 0.06 (20.06 to 0.19) 0.10 (20.01 to 0.21)
.350 96 (64.4) 53 (35.6)
Gestational age in weeks: median (IQR)
,20 wk 32 (54.2) 27 (45.8) 20.18 (20.31 to 20.06) 20.27 (20.39 to 20.14)
$20 wk 173 (72.7) 65 (27.3)
Baseline viral load
Undetectable 106 (68.0) 50 (32.0) 20.02 (20.13 to 0.09) 0.01 (20.09 to 0.11)
Detectable 95 (69.9) 41 (30.1)
Initial PMTCT regimen
ART 46 (70.8) 19 (29.2) 0.03 (20.10 to 0.17) 0.03 (20.10 to 0.17)
AZT 151 (67.4) 73 (32.6)
*Only participants with available pill counts data were considered. Stratified numbers across level of baseline characteristics might not add to N because of missing data.
†Adjusted for all baseline covariates in the table.
IQR, interquartile range.
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delivery, only 17% had their first visit within the first
trimester and less than half of them (48%) complete the
recommended minimum of 4 visits or more.22 Implementation
science research is needed to further address barriers to timely
and optimal utilization of MCH services, including PMTCT
in resource poor settings.
In addition to its randomized design, this study has
important strengths. All participants provided a DBS for viral
load; however, 6 patients were missing results at 6 weeks
because of either sample mishandling or inadequacy. Simi-
larly, adherence data were available for a large proportion of
participants (90%) and was collected routinely as part of
PMTCT monitoring. However, the study also has several
limitations. First, the study population was a subset of those
initially randomized. Despite that, baseline characteristics
remained balanced between study groups, the exchangeability
of potential outcomes cannot be guaranteed. Second, we do
not know which participants were retained in care specifically
because of the monetary incentives they received. It is
possible that adherence or virological suppression among
these participants in particular is higher than it would be
among other participants from the incentive and control
groups who were included in this analysis. However, even
if this were true, because we are interested in the total
population effect of financial incentives on ART adherence
and viral suppression, our strategy of comparing all partic-
ipants who were retained in care seems more appropriate.
In conclusion, the provision of cash incentives to HIV-
infected pregnant women led to higher retention in care at 6
weeks postpartum without any evidence of lower rates of
adherence to ARVs and virologic suppression than those who
did not receive the cash incentive.
ACKNOWLEDGMENTS
The authors are grateful for the participation and time of
the mothers and infants in the study, the time and efforts of the
personnel of the participating clinics, the technical support of
Drs. Landry Kiketa and Noro Lantoniaina Rosa Ravelomanana,
the data collection and data entry contributions of Josée Nlandu
Babela, Valerie B. Chalachala, Fanny Matadi, Espérance
Mindia, and Georges Kihuma Nganguli, and the support of
the Ohio State University’s, University of North Carolina’s, and
Kinshasa School of Public Health’s administrative teams.
REFERENCES
1. Pepfar 3.0—Controlling the Epidemic: Delivering on the Promise of an
AIDS-Free Generation. Available at: http://www.pepfar.gov/about/
strategy/. Accessed June 1, 2016.
2. PEPFAR. PEPFAR Blueprint: Creating an AIDS-Free Generation. The
Office of the U.S. Global AIDS Coordinator, Washington, DC. 2012.
3. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of
people with HIV according to timing of diagnosis. AIDS. 2012;26:335–343.
4. Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A, et al.
Short-course therapy with zidovudine plus lamivudine for prevention of
TABLE 3. Crude and Adjusted Differences in the Proportions of Participants With an Undetectable Viral Load at 6 Weeks
Postpartum, by Study Group
Undetectable Viral Load at 6 Weeks
Yes (N = 221)* No (N = 105)* RD (95% CI) Adjusted RD (95% CI)†
Group
Intervention 113 (66.1) 58 (33.9) 20.04 (20.14 to 0.07) 20.01 (20.10 to 0.08)
Control 108 (69.7) 47 (30.3)
Age in years: median (IQR) 29 (26 to 34) 28 (25 to 35) 20.00 (20.01 to 0.01) 0.00 (20.01 to 0.01)
Maternal education in years: median (IQR) 11 (8,12) 10 (8,12) 0.01 (20.01 to 0.03) 0.01 (20.01 to 0.02)
Marital status
Divorced/separated/widow/never married 36 (66.7) 18 (33.3) 20.02 (20.12 to 0.09) 0.04 (20.07 to 0.15)
Married/cohabiting 185 (68.3) 86 (31.7)
CD4 count
#350 111 (69.8) 48 (30.2) 0.01 (20.08 to 0.11) 20.03 (20.12 to 0.06)
.350 91 (71.1) 37 (28.9)
Gestational age in weeks: median (IQR)
,20 wk 48 (73.85) 17 (26.15) 0.08 (20.05 to 0.20) 0.04 (20.06 to 0.13)
$20 wk 173 (66.3) 88 (33.7)
Baseline viral load
Undetectable 140 (84.3) 26 (25.2) 0.34 (0.26 to 0.42) 0.32 (0.24 to 0.40)
Detectable 78 (50.3) 77 (49.7)
Initial PMTCT regimen
ART 58 (78.4) 16 (21.6) 0.14 (0.01 to 0.26) 0.08 (20.02 to 0.18)
AZT 158 (64.7) 86 (35.3)
*Only participants with available viral load result at 6 weeks postpartum were considered. Stratified numbers across level of baseline characteristics might not add to N because of
missing data.
†Adjusted for all baseline covariates in the table.
IQR, interquartile range.
Yotebieng et al J Acquir Immune Defic Syndr  Volume 72, Supplement 2, August 1, 2016
S128 | www.jaids.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
mother-to-child transmission of human immunodeficiency virus type 1 in
Thailand. Clin Infect Dis. 2002;35:1405–1413.
5. Babiker AG, Emery S, Fätkenheuer G, et al. Considerations in the
rationale, design and methods of the strategic timing of AntiRetroviral
treatment (start) study. Clin Trials. 2013;10:S5–S36.
6. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early
versus delayed initiation of antiretroviral treatment on clinical outcomes
of HIV-1 infection: results from the phase 3 HPTN 052 randomised
controlled trial. Lancet Infect Dis. 2014;14:281–290.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection
with early antiretroviral therapy. New Engl J Med. 2011;365:493–505.
8. Fowler MG, Qin M, Shapiro D, et al. PROMISE: Efficacy and Safety of 2
Strategies to Prevent Perinatal HIV Transmission. Conference on Retro-
viruses and Opportunistic Infections (CROI). Seattle, Washington; 2015.
9. United Nations General Assembly Special Session on HIV/AIDS; 2001.
United Nations, New York, NY. Available at: United Nations at http://
data.unaids.org/publications/irc-pub03/aidsdeclaration_en.pdf. Accessed
November 08, 2011.
10. Call to Action: Towards an HIV-Free and AIDS-Free Generation. Abuja,
Nigeria; 2005.
11. Prevention of Mother to Child Transmission (PMTCT) High Level Global
Partners Forum. World Health Organization. Achieving Universal Access
to Comprehensive PMTCT Services. Johannesburg, South Africa, 2007.
12. UNAIDS. 2014 Progress Report on the Global Plan Towards the
Elimination of New HIV Infections Among Children by 2015 and
Keeping Their Mothers Alive; 2014. Joint United Nations Programme
on HIV/AIDS (UNAIDS), Geneva, Switzerland.
13. World Health Organization. Consolidated Guidelines on the Use of
Antiretroviral Drugs for Treating and Preventing HIV Infection:
Recommendations for a Public Health Approach: World Health Orga-
nization; 2013. Geneva, Switzerland.
14. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal
antiretroviral therapy for HIV-infected pregnant and breastfeeding
women (“Option B+”) in Malawi. AIDS. 2014;28:589–598.
15. Sibanda E, Weller I, Hakim J, et al. The magnitude of loss to follow-up
of HIV-exposed infants along the prevention of mother-to-child HIV
transmission continuum of care: a systematic review and meta-analysis.
AIDS. 2013;27:2787–2797.
16. Global report UNAIDS. UNAIDS Report on the Global AIDS Epidemic
2013. Geneva, Switzerland; 2013:198.
17. Yotebieng M, Thirumurthy H, Moracco KE, et al. Conditional cash transfers
and uptake of and retention in prevention of mother-to-child HIV trans-
mission care: a randomised controlled trial. Lancet HIV. 2016;3:e85–e93.
18. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based
Preexposure prophylaxis for HIV infection among African women.
New Engl J Med. 2015;372:509–518.
19. Boillot F, Serrano L, Muwonga J, et al. Programmatic feasibility of dried
blood spots for the virological follow-up of patients on antiretroviral
treatment in Nord Kivu, Democratic Republic of the Congo. J Acquir
Immune Defic Syndr. 2016;71:e9–e15.
20. El-Khatib Z, Ekstrom A, Coovadia A, et al. Adherence and virologic
suppression during the first 24 weeks on antiretroviral therapy among
women in Johannesburg, South Africa—a prospective cohort study.
BMC Public Health. 2011;11:1–13.
21. Denoeud-Ndam L, Fourcade C, Ogouyemi-Hounto A, et al. Predictive
factors of plasma HIV suppression during pregnancy: a prospective
cohort study in Benin. PLoS One. 2013;8:e59446.
22. Ministére du Plan et Suivi de la Mise en oeuvre de la Révolution de la
Modernité (MPSMRM), Ministére de la Santé Publique (MSP) et ICF
International. Enquête Démographique et de Santé en République
Démocratique du Congo 2013-2014. Rockville, MD. MPSMRM, MSP
et ICF International; 2014; pages 696.
J Acquir Immune Defic Syndr  Volume 72, Supplement 2, August 1, 2016 Conditional Cash Transfers to Increase Retention
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | S129
